ScreenerHero

SGMTSagimet Biosciences Inc. Series A Common Stock

NAS · US · Technology · Biotechnology · sagimet.com
10.25USD-3.12%Mkt Cap: 637.13M $P/E: —

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap637.13M $
Enterprise Value394.59M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-51.04M $
Revenue/Share—
Last Price10.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorTechnology
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.59
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.24
EPS (TTM)-1.21
EPS (Forward)-1.34
52W Range
4.50086% of range11.15
52W High11.15 USD
52W Low4.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.82%
ROA-43.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.65M $
CapEx (TTM)—
FCF Margin—
FCF Yield-4.37%
Net Debt-238.19M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio45.02
Quick Ratio44.31
Book Value/Sh3.144 USD
Cash/Share3.863 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.60 USD
Upside (mean)+179.0%
Target Range8.000 USD – 56.00 USD
$8.000+179.0% to mean$56.00
# Analysts10
Ownership
Shares Out.61.59M
Float55.78M
Insiders3.35%
Institutions83.10%
Short Interest
Short Ratio13.1d
Short % Float19.11%
Short % Out.18.77%
Shares Short11.60M
Short (prev mo.)8.25M
Technical
SMA 507.803 (+31.4%)
SMA 2006.685 (+53.3%)
Beta3.40
S&P 52W Chg18.16%
Avg Vol (30d)1.18M
Avg Vol (10d)1.46M
Technical Indicators
RSI (14)70.2
MACD0.8094
MACD Signal0.6051
MACD Hist.+0.2044
BB Upper11.23 USD
BB Middle8.570 USD
BB Lower5.909 USD
BB Width62.10%
ATR (14)0.6239 USD
Vol Ratio (20d)0.80x